2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

4151 Tumor cells with compromised antigen presentation machinery: Mechanistic insights into resistance vs. sensitization to NK cells through CRISPR-based functional genomics studies

Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD2, Sara Gandolfi, MD, PhD3, Shizuka Yamano4, Lisa Leypoldt5, Olli Dufva6, Sofia Pasparaki, MD7, Eleni Anastasakou8, Satu Mustjoki, MD, PhD9, Constantine Mitsiades, MD, PhD10
1 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
2 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
3 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
5 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
6 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
8 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
9 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
10 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States

Extensive studies by multiple groups, including ours, have applied, in both hematologic neoplasias and solid tumors, CRISPR methods to examine the molecular mechanisms regulating the response vs. resistance of these tumor cells to natural killer (NK) cells, including allogeneic donor-derived primary NK cells and immortalized NK cell lines. Across these studies, loss of function (LOF) of antigen presentation machinery (APM) genes has been identified as the most potent and recurrent group of genomic perturbations that can sensitize tumor cells to NK cell cytotoxicity. However, to our knowledge, there has been limited systematic efforts to understand which additional molecular lesions could render APM-deficient tumor cells even more sensitive to NK cells or, conversely, cause them to be resistant to NK cell attack. This question is particularly relevant given that APM deficiency often facilitates the evasion of T-cell mediated immunity and immune checkpoint inhibitors.
Using CRISPR-based studies, we sought to identify additional genetic perturbations in APM-deficient cancer cells that could further enhance or, conversely, suppress NK cells mediated toxicity.
MM cell lines (KMS11 and MM.1S) with constitutive expression of the SpCas9 nuclease were electroporated with SpCas9-sgRNA ribonucleoprotein (RNP) complexes, which included sgRNAs targeting B2M or HLA-E, as key members of the class I HLA / APM pathway that are associated with NK cell resistance. Populations of cells with successful CRISPR gene editing and stable loss of B2M or HLA-E were purified by FACS. We confirmed that the sorted B2M- or HLA-E-deficient cells were more sensitive to NK cells that isogenic control cells; and that B2M gene knockout (KO) induced the most pronounced sensitization to NK cells, likely because B2M loss simultaneously suppresses not only HLA-E but also multiple other, typical and atypical, class I HLA molecules that otherwise inhibit NK activity.
We subsequently focused on genome-scale CRISPR KO screens (Brunello library) to identify genes modulating NK cell sensitivity in B2M-deficient MM cells vs. B2M-proficient isogenic cells. As expected, sgRNAs targeting B2M, HLA-E, and other APM components or regulators (e.g., TAPBP, TAP1, TAP2, ERAP1; the transcriptional regulators RFXAP, RFXANK, RFX5, NLRC5, etc.) did not show depletion in B2M-deficient cells under NK cell attack. This is in contrast to the pronounced depletion of these gene KOs in parallel screens with isogenic B2M-proficient cells and our prior CRISPR studies with other B2M-proficient tumor cell lines. Several other gene KOs cause NK cell sensitization in both B2M-proficient and -deficient tumor cells: these include genes involved in regulation of glycosylation (e.g., GANAB, SLC35A1,SLC35A2, CMAS, GALE, UXS1, MGAT1). The most pronounced and consistent enrichment of KOs among B2M KO MM cells that survived NK cell attack was observed for genes involved in the regulation of GPI-anchored proteins (or example, PIGP, PIGV, PIGA, PIGL, PIGW, PGAA1, PGAP2, PGAP3 and others). Notably, CD48 and CD58, both GPI-anchored ligands, were also among the genes whose KO promoted survival of B2M-deficient cells during NK attack. Among other notable genes identified from our CRISPR KO studies, KOs for ICAM1 are enriched in both B2M KO and control B2M-expressing cells that survive after NK cell attack, suggesting that ICAM1 plays an important role in engagement of NK cells and tumor cells independently of the tumor cell status of B2M and class I HLA. Furthermore, we observed that B2M deficient cells exhibit modest enrichment of CRISPR KO for JAK1 and NLRC5 (although these KOs are depleted in B2M-proficient tumor cells under NK cell attack); enrichment for KOs of sulfotransferases HS2ST1, HS3ST5 involved in the modification of carbohydrate backbone of heparan sulfate; as well as several other previously understudied putative regulators of immune response which are currently under further characterization.
Loss of the class I HLA/APM/IFN response pathway is a recurrent mechanism of T-cell escape but increases NK cell sensitivity. As APM-deficient tumors are prime targets for NK cell therapies, our study provides a framework to preemptively understand what additional biomarkers should be examined in patient tumors with genomic perturbations of the APM pathway in order to better assess their probability of responsiveness to NK cell-based therapies.

 

Olga Dashevsky, PhD: No relevant conflicts of interest to declare.